SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...
In a recent proof-of-concept study, researchers confirmed the feasibility of using CRISPR-armed phages to selectively target clinically-relevant...
Today, Danish company SNIPR Biome announced positive interim clinical results from its Phase 1 clinical trial of SNIPR001, the first CRISPR-armed...
SNIPR BIOME, Denmark, announced today that it has dosed the first human subjects in its Phase 1 clinical trial for SNIPR001, an orally administered...
2021 was a very successful year for CRISPR in the medical field. Much of the success comes down to gene editing without double-strand breaks,...
In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...
Some of the best links we picked up around the internet
Bugs are winning: WHO has issued dire warnings of 'the post-antibiotic era' in which any person regardless of age or country risk to suffer and die of...
